Author Archives for Adeline Chauvigné

Affilogic enters into a Research Collaboration and Licensing Agreement with Sanofi on Nanofitin-conjugated biotherapeutics

Affilogic announces the signature of a collaboration and license agreement with Sanofi for the development of Nanofitin®-conjugated biotherapeutics. Nantes –... View Article

Rédigé par Adeline Chauvigné, le 2016-07-04

Affilogic enters into a Research Collaboration and Licensing Agreement with Sanofi on Nanofitin-conjugated biotherapeutics

Affilogic announces the signature of a collaboration and license agreement with Sanofi for the development of Nanofitin®-conjugated biotherapeutics. Nantes –... View Article

Biofortis is pleased to announce its cooperation with Triskelion

Biofortis and Triskelion are pleased to announce the partnership signed between Biofortis, the innovation Center of Mérieux Nutrisciences, and Triskelion,... View Article

Rédigé par Adeline Chauvigné, le 2016-06-30

Biofortis is pleased to announce its cooperation with Triskelion

Biofortis and Triskelion are pleased to announce the partnership signed between Biofortis, the innovation Center of Mérieux Nutrisciences, and Triskelion,... View Article

Maryvonne Hiance Chairman of France Biotech

  Atlanpole Biotherapies is pleased to announce  the election of one of its iconic entrepreneur : Maryvonne Hiance, who is... View Article

Rédigé par Adeline Chauvigné, le 2016-07-20

Maryvonne Hiance Chairman of France Biotech

  Atlanpole Biotherapies is pleased to announce  the election of one of its iconic entrepreneur : Maryvonne Hiance, who is... View Article

Research Summer School

The University of Angers is very pleased to announce the Summer Schools Angers 2016. From 27th June to 8th July,... View Article

CESTI IHU: INNOVATION TOWARDS IMMUNE SYSTEM MODULATION

  CESTI IHU: towards an innovative therapy aiming at modulating the immune system The research program led by Prof. Karin... View Article

Rédigé par Adeline Chauvigné, le 2016-06-20

CESTI IHU: INNOVATION TOWARDS IMMUNE SYSTEM MODULATION

  CESTI IHU: towards an innovative therapy aiming at modulating the immune system The research program led by Prof. Karin... View Article

XENOTHERA closes a new capital increase above 2 million euros

XENOTHERA, a young biotech who develops an innovative immunosuppressant, has closed on June 2nd, 2016, a second fundraising for more... View Article

Rédigé par Adeline Chauvigné, le 2016-06-17

XENOTHERA closes a new capital increase above 2 million euros

XENOTHERA, a young biotech who develops an innovative immunosuppressant, has closed on June 2nd, 2016, a second fundraising for more... View Article

First sales of Flu Vaccines Produced on Valneva’s EB66® Cell-Line

First sales of Flu Vaccines Produced on Valneva’s EB66® Cell-Line Valneva to begin receiving royalties for an EB66®-based human vaccine... View Article

Rédigé par Adeline Chauvigné, le 2016-06-16

First sales of Flu Vaccines Produced on Valneva’s EB66® Cell-Line

First sales of Flu Vaccines Produced on Valneva’s EB66® Cell-Line Valneva to begin receiving royalties for an EB66®-based human vaccine... View Article

InFlectis BioScience raises €6 million

InFlectis BioScience raises €6 million in a Series A round to perform clinical trial in humans. Nantes, France – June... View Article

Rédigé par Adeline Chauvigné, le 2016-06-15

InFlectis BioScience raises €6 million

InFlectis BioScience raises €6 million in a Series A round to perform clinical trial in humans. Nantes, France – June... View Article

OSE Pharma merge with Effimune to create OSE Immunotherapeutics

OSE Pharma and Effimune shareholders approve merger to create OSE Immunotherapeutics Paris, Nantes, May 31, 2016 – OSE Pharma SA... View Article

Effimune, launch of an hepatocellular carcinoma study

OSE Pharma and Effimune announce the launch of a non-interventional study in hepatocellular carcinoma under a private-public collaborative program. Paris,... View Article

Rédigé par Adeline Chauvigné, le 2016-05-25

Effimune, launch of an hepatocellular carcinoma study

OSE Pharma and Effimune announce the launch of a non-interventional study in hepatocellular carcinoma under a private-public collaborative program. Paris,... View Article